LeadBio Announces Tens of Millions RMB Series A+ Financing from Tasly New Track Fund to Advance Clinical Development of Small-Diameter Bioengineered Vascular Grafts

VCBeat learned第一时间 that on June 12, 2024, LEADBIO (Hangzhou) Co., Ltd. ("LEADBIO") completed a financing round byHangzhou Tianshili New Racetrack Equity Investment Partnership (Limited Partnership)LEADBIO Secures Tens of Millions in A+ Round Financing, Following the Completion of Its A Round at the End of 2023

The funds from this round of financing will be mainly used for the clinical advancement of existing products and the research and development of new indications for coronary artery bypass artificial blood vessels, accelerating the progress of multiple preclinical studies and promoting LEADBIO's research and innovation in the field of regenerative medicine.

LEADBIO was established in February 2019, adhering to the mission of "applying technology and innovating healthcare." It is committed to the research and development of tissue-engineered artificial organs and organ preservation products that can replace and repair human tissues and organs, aspiring to become a global leader in regenerative medicine R&D and manufacturing. The company will continue to uphold the vision of "innovating for life," making full use of this financing to accelerate product development, clinical trials, and market expansion, providing more and better tissue-engineered artificial organs and organ preservation products for patients worldwide.

Mr. Wang Chen, Managing Partner of Tianshili CapitalRepresentation: Artificial blood vessels, especially small-caliber ones, present significant technical challenges and address substantial unmet clinical needs in applications such as renal dialysis fistulas and coronary artery bypass grafting. Small-caliber artificial blood vessels must balance the short-term establishment of vascular access with long-term patency while meeting clinical requirements based on general considerations like biocompatibility. We believe that bioengineered artificial blood vessels produced using novel degradable biomaterial scaffolds, cell culture, and decellularization techniques—combined with regenerative medicine, functional biomaterials, and tissue engineering—are most likely to meet these clinical demands at this stage. In the future, such products could further evolve by integrating advancements in gene editing and stem cell technology, enhancing performance through the action of inducing factors on endogenous stem cells. LEADBIO, a leading company in this field in China under the guidance of Professor Kong Deling's team, has accumulated extensive experience and technological expertise. We are honored to invest in LEADBIO and are attracted by the scientific, objective, and rigorous corporate culture of Professor Kong’s team. We will spare no effort to support LEADBIO in completing small-caliber artificial blood vessel products that meet clinical requirements as soon as possible, benefiting a wide range of patients. We will also continue to support LEADBIO’s advancement in this field, helping it lead the industry forward.

Relying on the industrial resources of its shareholder, Tianshili Holding Group, and adhering to the concept of industrial investment, the company persists in the 4D investment strategy. It focuses on building an ecosystem for the pharmaceuticals, medical devices, diagnostics, and digital health industries around disease areas such as cardiovascular, oncology, metabolism, and gastroenterology. The company is committed to assisting start-up and growth-stage enterprises. Since its establishment in 2007, the company has managed a scale exceeding 10 billion yuan, with seven RMB funds and three USD funds successively. It has invested in over 100 projects cumulatively and exited more than 30 projects, including 16 successful IPOs; among them are well-known industry enterprises such as Innovent Biologics, Leadbio, CARsgen Therapeutics, I-Mab, Berry Genomics, Xinwei Medical, and Northland Biotech.